Recent advancements, limitations, and future perspectives of the use of personalized medicine in treatment of colon cancer

A Dey, A Mitra, S Pathak, S Prasad… - … in Cancer Research …, 2023 - journals.sagepub.com
Due to the heterogeneity of colon cancer, surgery, chemotherapy, and radiation are
ineffective in all cases. The genomic profile and biomarkers associated with the process are …

[HTML][HTML] Towards a better understanding of light-glucose induced modifications on the structure and biological activity of formulated Nivolumab

E De Diana, E Rizzotto, I Inciardi, L Menilli… - International Journal of …, 2024 - Elsevier
In the last years, monoclonal antibodies (mAbs) have rapidly escalated as
biopharmaceuticals into cancer treatments, mainly for their target specificity accompanied by …

[HTML][HTML] Synthesis and evaluation of amyloid beta peptide/Ruthenium III-based complex drugs as drug delivery and anticancer activity

R Senthil - Toxicology Reports, 2024 - Elsevier
The development and characterization of anticancer complex drugs (ACD), specifically
Amyloid Beta Peptide (ABP)-Ruthenium III (Ru III)-nivolumab (NB), were explored through …

Comprehensive physicochemical and functional analysis of pembrolizumab based on controlled degradation studies: Impact on antigen–antibody binding

A Torrente-López, J Hermosilla… - European Journal of …, 2024 - Elsevier
Monoclonal antibodies-based medicines are widely used in the treatment of different
diseases. These medicines are very sensitive to exposure to different environmental …

Site-Specific Structural Changes in Long-Term-Stressed Monoclonal Antibody Revealed with DEPC Covalent-Labeling and Quantitative Mass Spectrometry

M Gaikwad, F Richter, R Götz, A Dörrbaum… - Pharmaceuticals, 2023 - mdpi.com
Studies of structural changes in mAbs under forced stress and storage conditions are
essential for the recognition of degradation hotspots, which can be further remodeled to …

[HTML][HTML] Development of a Mammalian Cell Line for Stable Production of Anti-PD-1

E Csató-Kovács, P Salamon, S Fikó-Lászlo, K Kovács… - Antibodies, 2024 - mdpi.com
Background/Objectives: Immune checkpoint blockade, particularly targeting the
programmed cell death 1 (PD-1) receptor, is a promising strategy in cancer immunotherapy …

[HTML][HTML] Comprehensive Analysis of Cetuximab Critical Quality Attributes: Impact of Handling on Antigen-Antibody Binding

A Torres-García, A Torrente-López, J Hermosilla… - Pharmaceutics, 2024 - mdpi.com
Background/Objectives: Cetuximab, formulated in Erbitux®(5 mg/mL), is a therapeutic
monoclonal antibody (mAb) widely used in several cancer treatments. Currently, there is …

Characterization of therapeutic antibody charge heterogeneity under stress conditions by microfluidic capillary electrophoresis coupled with mass spectrometry

Z Wu, H Wang, X Zhao, C Gong, S Sidnam… - Journal of …, 2024 - Elsevier
Therapeutic antibodies are a major class of biopharmaceutics that are applied in disease
treatment because of their many advantages, including high specificity and high affinity to …

[HTML][HTML] Protein nanoparticles as potent delivery vehicles for polycytosine RNA-binding protein one

ZY Zhao, PL Luo, X Guo, ZW Huang - World Journal of Diabetes, 2025 - wjgnet.com
Ma et al recently reported in the World Journal of Diabetes that ferroptosis occurs in
osteoblasts under high glucose conditions, reflecting diabetes pathology. This condition …

Development and biophysical characterization of a humanized FSH–blocking monoclonal antibody therapeutic formulated at an ultra-high concentration

S Rojekar, AR Pallapati, J Gimenez-Roig, F Korkmaz… - Elife, 2023 - elifesciences.org
Highly concentrated antibody formulations are oftentimes required for subcutaneous, self-
administered biologics. Here, we report the development of a unique formulation for our first …